<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - OSELTAMIVIR</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>OSELTAMIVIR</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#drugAction" data-toggle="tab">Drug action</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#directionsForAdministration" data-toggle="tab">Administration</a></li>
          <li><a href="#patientAndCarerAdvice" data-toggle="tab">Patient and carer advice</a></li>
          <li><a href="#nationalFunding" data-toggle="tab">National funding/access decisions</a></li>
          <li><a href="#unlicensedUse" data-toggle="tab">Unlicensed use</a></li>
          <li><a href="#prescribingAndDispensingInformation" data-toggle="tab">Prescribing and dispensing</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Prevention of influenza</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                75 mg once daily for 10 days for post-exposure prophylaxis; for up to 6 weeks during an epidemic.</li>
              <li class="dose child"><strong>For children 1&#8211;2 months</strong><br/>
                2.5 mg/kg once daily for 10 days for post-exposure prophylaxis.</li>
              <li class="dose child"><strong>For children 3&#8211;11 months</strong><br/>
                3 mg/kg once daily for 10 days for post-exposure prophylaxis.</li>
              <li class="dose child"><strong>For children 1&#8211;12 years (body-weight 10&#8211;15 kg)</strong><br/>
                30 mg once daily for 10 days for post-exposure prophylaxis; for up to 6 weeks during an epidemic.</li>
              <li class="dose child"><strong>For children 1&#8211;12 years (body-weight 16&#8211;23 kg)</strong><br/>
                45 mg once daily for 10 days for post-exposure prophylaxis; for up to 6 weeks during an epidemic.</li>
              <li class="dose child"><strong>For children 1&#8211;12 years (body-weight 24&#8211;40 kg)</strong><br/>
                60 mg once daily for 10 days for post-exposure prophylaxis; for up to 6 weeks during an epidemic.</li>
              <li class="dose child"><strong>For children 1&#8211;12 years (body-weight 41 kg and above)</strong><br/>
                75 mg once daily for 10 days for post-exposure prophylaxis; for up to 6 weeks during an epidemic.</li>
              <li class="dose child"><strong>For children 13&#8211;17 years</strong><br/>
                75 mg once daily for 10 days for post-exposure prophylaxis; for up to 6 weeks during an epidemic.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Treatment of influenza</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                75 mg twice daily for 5 days.</li>
              <li class="dose child"><strong>For children 1&#8211;2 months</strong><br/>
                2.5 mg/kg twice daily for 5 days.</li>
              <li class="dose child"><strong>For children 3&#8211;11 months</strong><br/>
                3 mg/kg twice daily for 5 days.</li>
              <li class="dose child"><strong>For children 1&#8211;12 years (body-weight 10&#8211;15 kg)</strong><br/>
                30 mg twice daily for 5 days.</li>
              <li class="dose child"><strong>For children 1&#8211;12 years (body-weight 16&#8211;23 kg)</strong><br/>
                45 mg twice daily for 5 days.</li>
              <li class="dose child"><strong>For children 1&#8211;12 years (body-weight 24&#8211;40 kg)</strong><br/>
                60 mg twice daily for 5 days.</li>
              <li class="dose child"><strong>For children 1&#8211;12 years (body-weight 41 kg and above)</strong><br/>
                75 mg twice daily for 5 days.</li>
              <li class="dose child"><strong>For children 13&#8211;17 years</strong><br/>
                75 mg twice daily for 5 days.</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>


      <section class="tab-pane" id="drugAction">
        <h2>Drug action</h2>

            <section class="drugAction">
              <p>Reduces replication of influenza A and B viruses by inhibiting viral neuraminidase.</p>
            </section>
      </section>

      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Although safety data are limited, oseltamivir can be used in women who are pregnant when the potential benefit outweighs the risk (e.g. during a pandemic).</p>
            </section>
            <section class="generalInformation">
              <p>Use only if potential benefit outweighs risk (e.g. during a pandemic).</p>
            </section>
      </section>


      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

            <section class="doseAdjustments">
              <h3 class="specificity">In adults</h3>
              <p>For <i>treatment</i>, use 30&#8239;mg twice daily if eGFR 30&#8211;60&#8239;mL/minute/1.73&#8239;m<sup>2 </sup> (30&#8239;mg once daily if eGFR 10&#8211;30&#8239;mL/minute/1.73&#8239;m<sup>2</sup>).</p><p>For <i>prevention</i>, use 30&#8239;mg once daily if eGFR 30&#8211;60&#8239;mL/minute/1.73&#8239;m<sup>2</sup> (30&#8239;mg every 48 hours if eGFR 10&#8211;30&#8239;mL/minute/1.73&#8239;m<sup>2</sup>).</p>
            </section>
            <section class="doseAdjustments">
              <h3 class="specificity">In children</h3>
              <p>For <i>treatment</i>, use 40% of normal dose twice daily if estimated glomerular filtration rate 30&#8211;60&#8239;mL/minute/1.73&#8239;m<sup>2 </sup> (40% of normal dose once daily if estimated glomerular filtration rate 10&#8211;30&#8239;mL/ minute/1.73&#8239;m<sup>2</sup>).</p><p>For <i>prevention</i>, use 40% of normal dose once daily if estimated glomerular filtration rate 30&#8211;60&#8239;mL/minute/1.73&#8239;m<sup>2</sup> (40% of normal dose every 48 hours if estimated glomerular filtration rate 10&#8211;30&#8239;mL/minute/1.73&#8239;m<sup>2</sup>).</p>
            </section>
        
            <section class="generalInformation">
              <h3 class="specificity">In adults</h3>
              <p>Avoid for <i>treatment</i> and <i>prevention</i> if eGFR less than 10&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p>
            </section>
            <section class="generalInformation">
              <h3 class="specificity">In children</h3>
              <p>Avoid for <i>treatment</i> and <i>prevention</i> if estimated glomerular filtration rate less than 10&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p>
            </section>
      </section>


      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> Abdominal pain, dyspepsia, headache, nausea, vomiting,
              </p>
              <p>
                <strong>uncommon:</strong> Altered consciousness in children, altered consciousness (usually in children and adolescents) in adults, arrhythmias, convulsions, eczema, rash,
              </p>
              <p>
                <strong>rare:</strong> Gastro-intestinal bleeding, hepatitis, neuropsychiatric disorders in children, neuropsychiatric disorders (usually in children and adolescents) in adults, Stevens-Johnson syndrome, thrombocytopenia, toxic epidermal necrolysis, visual disturbances,
              </p>
        
        
        
      </section>

      <section class="tab-pane" id="directionsForAdministration">
        <h2>Directions for administration</h2>

            <section class="directionsForAdministration">
              <p>If suspension not available, capsules can be opened and the contents mixed with a small amount of sweetened food, such as sugar water or chocolate syrup, just before administration.</p>
            </section>
      </section>

      <section class="tab-pane" id="patientAndCarerAdvice">
        <h2>Advice for patients and carers</h2>

            <section class="patientResources">
              <h3 class="specificity">In children</h3>
                <p class="title">Medicines for Children leaflet: Oseltamivir for influenza (flu)</p>
              <p>
            <xref format="html" href="http://www.medicinesforchildren.org.uk/oseltamivir-for-influenza">www.medicinesforchildren.org.uk/oseltamivir-for-influenza</xref>
            </p>
            </section>
      </section>

      <section class="tab-pane" id="nationalFunding">
        <h2>National funding/access decisions</h2>

            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA158</h3>
              <p outputclass="specificity">In adults</p> <p outputclass="title">Oseltamivir, zanamivir, and amantadine for prophylaxis of influenza (September 2008)</p> <p>Oseltamivir is <b>not</b> a substitute for vaccination, which remains the most effective way of preventing illness from influenza.</p> <ul> <li>Oseltamivir is <b>not</b> recommended for seasonal prophylaxis against influenza.</li> <li>When influenza is circulating in the community, oseltamivir is an option recommended (in accordance with UK licensing) for post-exposure prophylaxis in at-risk patients who are not effectively protected by influenza vaccine, and who have been in close contact with someone suffering from influenza-like illness in the same household or residential setting. Oseltamivir should be given within 48 hours of exposure to influenza. (National surveillance schemes, including those run by Public Health England, should be used to indicate when influenza is circulating in the community.)</li> <li>During local outbreaks of influenza-like illness, when there is a high level of certainty that influenza is present, oseltamivir may be used for post-exposure prophylaxis in at-risk patients (regardless of influenza vaccination) living in long-term residential or nursing homes.</li> </ul> <p>At risk patients include those aged over 65 years <i>or</i> those who have one or more of the following conditions:</p> <ul> <li>chronic respiratory disease (including asthma and chronic obstructive pulmonary disease);</li> <li>chronic heart disease;</li> <li>chronic renal disease;</li> <li>chronic liver disease;</li> <li>chronic neurological disease;</li> <li>immunosuppression;</li> <li>diabetes mellitus.</li> </ul> <p>The Department of Health in England has advised (November 2010 and April 2011) that &#8216;at risk patients&#8217; also includes patients under 65 years of age who are at risk of developing medical complications from influenza (treatment only) or women who are pregnant.</p> <p>This guidance does not cover the circumstances of a pandemic, an impending pandemic, or a widespread epidemic of a new strain of influenza to which there is little or no immunity in the community. </p><xref format="html" href="http://www.nice.org.uk/TA158">www.nice.org.uk/TA158</xref>
                <a href="http://www.nice.org.uk/TA158" target="_blank">www.nice.org.uk/TA158</a>
            </section>
            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA158</h3>
              <p outputclass="specificity">In children</p> <p outputclass="title">Oseltamivir, zanamivir, and amantadine for prophylaxis of influenza (September 2008)</p> <p>Oseltamivir is <b>not</b> a substitute for vaccination, which remains the most effective way of preventing illness from influenza.</p> <ul> <li>Oseltamivir is <b>not</b> recommended for seasonal prophylaxis against influenza.</li> <li>When influenza is circulating in the community, oseltamivir is a treatment option recommended (in accordance with UK licensing) for post-exposure prophylaxis in at-risk patients who are not effectively protected by influenza vaccine, and who have been in close contact with someone suffering from influenza-like illness in the same household or residential setting. Oseltamivir should be given within 48 hours of exposure to influenza. (National surveillance schemes, including those run by Public Health England, should be used to indicate when influenza is circulating in the community.)</li> <li>During local outbreaks of influenza-like illness, when there is a high level of certainty that influenza is present, oseltamivir may be used for post-exposure prophylaxis in at-risk patients (regardless of influenza vaccination) living in long-term residential or nursing homes.</li> </ul> <p>At risk patients are those who have one or more of the following conditions:</p> <ul> <li>chronic respiratory disease (including asthma);</li> <li>chronic heart disease;</li> <li>chronic renal disease;</li> <li>chronic liver disease;</li> <li>chronic neurological disease;</li> <li>immunosuppression;</li> <li>diabetes mellitus.</li> </ul> <p>The Department of Health in England has advised (November 2010 and April 2011) that &#8216;at risk patients&#8217; also includes children who are at risk of developing medical complications from influenza (treatment only) or females who are pregnant.</p> <p>This guidance does not cover the circumstances of a pandemic, an impending pandemic, or a widespread epidemic of a new strain of influenza to which there is little or no immunity in the community. </p><xref format="html" href="http://www.nice.org.uk/TA158">www.nice.org.uk/TA158</xref>
                <a href="http://www.nice.org.uk/TA158" target="_blank">www.nice.org.uk/TA158</a>
            </section>
            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA168</h3>
              <p outputclass="specificity">In adults</p> <p outputclass="title">Oseltamivir, zanamivir, and amantadine for treatment of influenza (February 2009)</p> <p>Oseltamivir is not a substitute for vaccination, which remains the most effective way of preventing illness from influenza.</p> <ul> <li>When influenza is circulating in the community, oseltamivir is an option recommended (in accordance with UK licensing) for the treatment of influenza in at-risk patients who can start treatment within 48 hours of the onset of symptoms. (National surveillance schemes, including those run by Public Health England, should be used to indicate when influenza is circulating in the community.)</li> <li>During local outbreaks of influenza-like illness, when there is a high level of certainty that influenza is present, oseltamivir may be used for treatment in at-risk patients living in long-term residential or nursing homes.</li> </ul> <p>At risk patients include those aged over 65 years <i>or</i> those who have one or more of the following conditions:</p> <ul> <li> chronic respiratory disease (including asthma and chronic obstructive pulmonary disease);</li> <li>chronic heart disease;</li> <li>chronic renal disease;</li> <li>chronic liver disease;</li> <li>chronic neurological disease;</li> <li>immunosuppression;</li> <li>diabetes mellitus.</li> </ul> <p>The Department of Health in England has advised (November 2010 and April 2011) that &#8216;at risk patients&#8217; also includes patients under 65 years of age who are at risk of developing medical complications from influenza (treatment only) or women who are pregnant.</p> <p>This guidance does not cover the circumstances of a pandemic, an impending pandemic, or a widespread epidemic of a new strain of influenza to which there is little or no immunity in the community.</p><xref format="html" href="http://www.nice.org.uk/TA168">www.nice.org.uk/TA168</xref>
                <a href="http://www.nice.org.uk/TA168" target="_blank">www.nice.org.uk/TA168</a>
            </section>
            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA168</h3>
              <p outputclass="specificity">In children</p> <p outputclass="title">Oseltamivir, zanamivir, and amantadine for treatment of influenza (February 2009)</p> <p>Oseltamivir is not a substitute for vaccination, which remains the most effective way of preventing illness from influenza.</p> <ul> <li>When influenza is circulating in the community, oseltamivir is an option recommended (in accordance with UK licensing) for the treatment of influenza in at-risk patients who can start treatment within 48 hours of the onset of symptoms. (National surveillance schemes, including those run by Public Health England, should be used to indicate when influenza is circulating in the community.)</li> <li>During local outbreaks of influenza-like illness, when there is a high level of certainty that influenza is present, oseltamivir may be used for treatment in at-risk patients living in long-term residential or nursing homes.</li> </ul> <p>At risk patients are those who have one or more of the following conditions:</p> <ul> <li> chronic respiratory disease (including asthma and chronic obstructive pulmonary disease);</li> <li>chronic heart disease;</li> <li>chronic renal disease;</li> <li>chronic liver disease;</li> <li>chronic neurological disease;</li> <li>immunosuppression;</li> <li>diabetes mellitus.</li> </ul> <p>The Department of Health in England has advised (November 2010 and April 2011) that &#8216;at risk patients&#8217; also includes children who are at risk of developing medical complications from influenza (treatment only) or females who are pregnant.</p> <p>This guidance does not cover the circumstances of a pandemic, an impending pandemic, or a widespread epidemic of a new strain of influenza to which there is little or no immunity in the community.</p><xref format="html" href="http://www.nice.org.uk/TA168">www.nice.org.uk/TA168</xref>
                <a href="http://www.nice.org.uk/TA168" target="_blank">www.nice.org.uk/TA168</a>
            </section>
      </section>





      <section class="tab-pane" id="unlicensedUse">
        <h2>Unlicensed use</h2>

            <section class="unlicensedUse">
              <h3 class="specificity">In children</h3>
              <p>Not licensed for use in children under 1 year of age unless there is a pandemic.</p>
            </section>
      </section>

      <section class="tab-pane" id="prescribingAndDispensingInformation">
        <h2>Information regarding prescribing and dispensing</h2>

            <section class="prescribingAndDispensingInformation">
              <p>Flavours of oral liquid formulations may include tutti-frutti.</p>
            </section>
      </section>









      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of OSELTAMIVIR</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        
          <strong>Forms available from special-order manufacturers include: </strong>
            oral solution,
            oral suspension,

            <div id="PHP76623"><a href="../medicinalForm/PHP76623.html" data-target="#PHP76623" data-action="load">Capsule</a></div>
            <div id="PHP76637"><a href="../medicinalForm/PHP76637.html" data-target="#PHP76637" data-action="load">Oral suspension</a></div>
            <div id="PHP76629"><a href="../medicinalForm/PHP76629.html" data-target="#PHP76629" data-action="load">Oral solution</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
